Nerlynx (Neratinib) for Breast Cancer

Overview
Nerlynx is a prescription drug approved by the U.S. Food and Drug Administration (FDA) as adjuvant (post-surgery) treatment for adults with early stage breast cancer in which HER2 is overexpressed or amplified. Nerlynx is indicated for extended use after therapy with trastuzumab. Nerlynx is also referred to by its drug name, neratinib.

In about 25 percent of breast cancers, there is a genetic variation that causes tumor cells to produce extra receptors for a growth factor. This gene, known as HER2 or human epidermal growth factor receptor 2, causes the cancer to grow more aggressively. Nerlynx is a member of a class of drugs called kinase inhibitors, and it is designed to inhibit the growth of cancer cells with the HER2 gene. Nerlynx is believed to work by interfering with the growth of HER2-positive cancer cells, thereby slowing the growth of tumors.

How do I take it?
Prescribing information states that Nerlynx is taken once daily with meals.

Nerlynx comes in tablet form.

Side effects
The FDA-approved label for Nerlynx lists common side effects including fatigue, fever, rash, nosebleeds, dry skin, changes to nails, muscle spasms, nausea, diarrhea, vomiting, abdominal pain and bloating, loss of appetite, weight loss, and urinary tract infections.

Rare but serious side effects listed for Nerlynx include severe diarrhea, liver damage, and fetal harm in pregnant women.

For more details about this treatment, visit:

Nerlynx — Puma Biotechnology
https://nerlynx.com